Masior Ł, Grąt M, Krasnodębski M, Patkowski W, Figiel W, Bik E, Krawczyk M
Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Transplant Proc. 2016 Jun;48(5):1717-20. doi: 10.1016/j.transproceed.2016.01.055.
Despite great progress and improvement in results of orthotopic liver transplantation (OLTx), 10%-20% of patients still require retransplantation (re-OLTx). The aim of the study was to present long-term results of liver retransplantation and to determine the factors influencing outcomes.
From December 1994 to July 2014, a total of 1461 liver transplantations were performed in the Department of General, Transplant and Liver Surgery of Medical University of Warsaw. There were 92 retransplantations (6.3%), including 40 early re-OLTx (up to 30 days). The most common indication for re-OLTx were vascular complications (41/92, 44.6%). Influence of clinical variables on short- and long-term outcomes was analyzed.
Postoperative mortality was 30.4% (28/92). One-year, 3-year and 5-year survival for all patients was 59.8%, 56.5% and 54.1%, respectively. The best results were achieved in patients undergoing retransplantation due to chronic rejection and biliary complications, whose 5-year survival rates were 75.0% and 72.9% respectively. There was no difference in long-term survival after early and late retransplantations (60.9% and 49.3%, respectively; P = .158). Multivariable analysis revealed factors associated with longer survival of patients, namely, higher preoperative hemoglobin concentration (P = .001), increased blood transfusions (P = .048), and decreased fresh frozen plasma transfusions (P = .004).
Liver retransplantation is a method providing satisfactory outcomes in selected patients. The perioperative period has a major impact on patient outcome.
尽管原位肝移植(OLTx)的结果取得了巨大进展和改善,但仍有10%-20%的患者需要再次移植(再次OLTx)。本研究的目的是呈现肝再次移植的长期结果,并确定影响预后的因素。
1994年12月至2014年7月,华沙医科大学普通、移植与肝脏外科共进行了1461例肝移植手术。其中有92例再次移植(6.3%),包括40例早期再次OLTx(30天内)。再次OLTx最常见的指征是血管并发症(41/92,44.6%)。分析了临床变量对短期和长期预后的影响。
术后死亡率为30.4%(28/92)。所有患者的1年、3年和5年生存率分别为59.8%、56.5%和54.1%。因慢性排斥反应和胆道并发症接受再次移植的患者取得了最佳结果,其5年生存率分别为75.0%和72.9%。早期和晚期再次移植后的长期生存率无差异(分别为60.9%和49.3%;P = 0.158)。多变量分析显示与患者较长生存期相关的因素,即术前血红蛋白浓度较高(P = 0.001)、输血增加(P = 0.048)和新鲜冰冻血浆输注减少(P = 0.004)。
肝再次移植是一种为特定患者提供满意预后的方法。围手术期对患者预后有重大影响。